Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare · Biotech & pharma
The global renal denervation market is projected to grow from USD 1.44 billion in 2026 to USD 8.64 billion by 2036, at a CAGR of 19.6%. Growth is driven by rising resistant and uncontrolled hypertension, positive clinical trial results, regulatory approvals, reimbursement expansion, and advances in radiofrequency, ultrasound, and micro-infusion technologies. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key products, technologies, indications, end users, regions, competitive strategies, and companies shaping this minimally invasive hypertension treatment market.
The global renal denervation market is projected to grow from USD 1.44 billion in 2026 to USD 8.64 billion by 2036, at a CAGR of 19.6%. Growth is driven by rising resistant and uncontrolled hypertension, positive clinical trial results, regulatory approvals, reimbursement expansion, and advances in radiofrequency, ultrasound, and micro-infusion technologies. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key products, technologies, indications, end users, regions, competitive strategies, and companies shaping this minimally invasive hypertension treatment market.
Sep 4 · 14:54·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(September 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...
Sep 4 · 14:45·Newsfile
Biotech & pharma
NASHVILLE, Tenn., Sept. 4, 2026 -- Radiation Business Solutions (RBS) urges radiation oncology providers and industry leaders nationwide to join ongoing advocacy efforts concerning the CMS proposed CY 2027 Medicare Physician Fee Schedule. While CMS has proposed increases for...
Sep 4 · 12:02·PR Newswire
Finance · Healthcare
CARLSBAD, Calif., Sept. 4, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that...
Sep 4 · 12:00·PR Newswire
Finance · Biotech & pharma
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
Sep 4 · 12:00·GlobeNewswire
Finance · Biotech & pharma
SAN CARLOS, Calif., Sept. 04, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
Sep 4 · 12:00·GlobeNewswire
Finance · Healthcare
DALLAS, Sept. 04, 2026 -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 4 · 12:00·GlobeNewswire
Finance · Biotech & pharma
CAMBRIDGE, Mass., Sept. 04, 2026 -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.
Sep 4 · 12:00·GlobeNewswire
Finance · Healthcare
PRINCETON, N.J., Sept. 04, 2026 -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.
Sep 4 · 12:00·GlobeNewswire
Healthcare · Biotech & pharma
London, United Kingdom--(September 4, 2026) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron's clinical strategy has taken an important turn with the announcement of an investigator-sponsored exploratory study of HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), led by Vanderbilt Health. Percheron's contribution will be limited to providing the study drug, a financial grant and advisory support. Following the announcement, the...
Sep 4 · 09:00·Newsfile
Biotech & pharma
4 September 2026 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], triggered by the entry of the oral NRF2 activator programme into the clinic.
Sep 4 · 07:00·GlobeNewswire
Healthcare · Biotech & pharma
- Oral Presentation in Session VI: Hereditary Angioedema SHANGHAI and NEW YORK, Sept. 4, 2026 -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that updated Phase II data from its ongoing...
Sep 4 · 06:00·PR Newswire